Loading...
Loading...
Commonwealth Bank increased its rating on ResMed
RMD from Hold to Buy after the company reported strong fourth quarter results that beat expectations.
Commonwealth Bank commented, "Gross margin outperformance to continue: Gross margin expansion was driven by a combination of positive product mix (Bi-level, APAP and masks) and manufacturing efficiencies (S9 platform consolidation), which more than offset FX headwinds. We expect these two factors will continue to boost FY13 gross margins with: 1) ongoing transition to HST driving further growth in higher-margin APAP devices, 2) continued strength in high-end bi-level sales with the launch of the VPAP ST and STA models on the S9 platform, and 3) ongoing share gains in masks."
ResMed closed at $35.29 on Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in